Latest News

BCE (TSX:BCE) stock may have reduced its dividend, but it's in better shape today and could be on the path back to growth.

These three global industrial giants can help Canadians diversify beyond banks and energy, while tapping aerospace, automation, and electrification tailwinds.

Enghouse is a profitable Canadian software company that looks cheaper now, even as it keeps generating cash.

Micron is riding an AI memory crunch, but how long will it last?

It's reaching into its coffers for a $5.6 billion acquisition.

These two Canadian growth stocks are showing strong momentum and could deliver big gains in 2026.

Allied Properties looks battered after a brutal sell-off, but a dividend reset and debt-reduction plan could set up a long recovery.

If you want long-term wealth builders on the TSX, one offers instant diversification while the other compounds through insurance profits and smart investing.

Want to put $21,000 in a TFSA to work? A high-yield monthly payer like Timbercreek can turn it into tax-free cash flow surprisingly fast.

This TSX compounder is down from its highs, but the business is still growing and buying more growth.

This global oilfield services provider reported a notable insider sale amid strong one-year share gains and ongoing sector expansion.

This AI-powered defense stock can benefit from a massive increase in the Pentagon's spending.

This small-cap Canadian oil producer looks set up for 2026 growth after beating production guidance and improving its balance sheet.

This beaten-down TSX dividend payer is quietly boosting cash flow, buying back units, and raising its monthly payout.

Stocks “prove doubters wrong” when scary narratives fade and improving cash flow forces a sentiment reset.

It posted its latest earnings report and announced a C-Suite transition.

An alliance with an artificial intelligence (AI) titan should help to fuel the semiconductor supplier's growth.

The Oracle of Omaha made a surprising final pick that's already paying off.

Could Exelixis be the next big player in cancer treatment? Join us as we explore its potential and the risks involved in this exciting investment opportunity.